Antibody Drug Discovery
Title | Antibody Drug Discovery PDF eBook |
Author | Clive R. Wood |
Publisher | World Scientific |
Pages | 490 |
Release | 2012 |
Genre | Medical |
ISBN | 1848166281 |
Antibody-based therapeutics are a central driver of the success of biopharmaceuticals. The discovery technology of this field is isolated to a limited number of centers of excellence in industry and academia. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field. Each chapter is written with a historical perspective that sets into context the significance of the key developments, and with the provision of “points to consider” for the reader as a value-added feature of the volume. All contributors are experts in their fields and have played pivotal roles in the creation of the technology.
Antibody-Drug Conjugates
Title | Antibody-Drug Conjugates PDF eBook |
Author | Kenneth J. Olivier, Jr. |
Publisher | John Wiley & Sons |
Pages | 567 |
Release | 2016-11-14 |
Genre | Medical |
ISBN | 1119060842 |
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Innovations for Next-Generation Antibody-Drug Conjugates
Title | Innovations for Next-Generation Antibody-Drug Conjugates PDF eBook |
Author | Marc Damelin |
Publisher | Springer |
Pages | 358 |
Release | 2018-05-29 |
Genre | Medical |
ISBN | 3319781545 |
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Antibody-Drug Conjugates and Immunotoxins
Title | Antibody-Drug Conjugates and Immunotoxins PDF eBook |
Author | Gail Lewis Phillips |
Publisher | Springer Science & Business Media |
Pages | 370 |
Release | 2012-12-13 |
Genre | Medical |
ISBN | 1461454565 |
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Antibody-Drug Conjugates
Title | Antibody-Drug Conjugates PDF eBook |
Author | Kenneth J. Olivier, Jr. |
Publisher | John Wiley & Sons |
Pages | 572 |
Release | 2016-11-14 |
Genre | Medical |
ISBN | 1119060680 |
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Cytotoxic Payloads for Antibody–Drug Conjugates
Title | Cytotoxic Payloads for Antibody–Drug Conjugates PDF eBook |
Author | David E Thurston |
Publisher | Royal Society of Chemistry |
Pages | 502 |
Release | 2019-07-11 |
Genre | Medical |
ISBN | 1788018451 |
Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.
Development of Antibody-Based Therapeutics
Title | Development of Antibody-Based Therapeutics PDF eBook |
Author | Mohammad A. Tabrizi |
Publisher | Springer |
Pages | 257 |
Release | 2018-09-11 |
Genre | Medical |
ISBN | 9811304963 |
With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students.